Lukasz Bojarski, PhD
Executive Director, AI in RBQM
Bio:
Lukasz received his PhD in Biochemistry from the Nencki Institute of Experimental Biology, Polish Academy of Sciences. After a successful career in academia, he joined the pharmaceutical industry in 2009. He initially worked on preclinical development programmes at Celon Pharma S.A., where he led several drug discovery projects in psychiatric and metabolic diseases. Some of these projects have since progressed into the clinical development phase. Lukasz later moved into clinical monitoring roles at Quintiles Inc. (now IQVIA) and subsequently at Covance, before joining the Centralized Monitoring Team at AstraZeneca in 2016. Between 2018 and 2026, Lukasz led the Centralized Monitoring group, which supported study teams in study de-risking and the identification of areas critical to study quality. During the study execution phase, the team conducted continuous central monitoring of study data to identify risk signals at the study, country, and site levels. Since early 2026, Lukasz has been leading a transformational project focused on evolving RBQM into a harmonized, AI-powered study oversight engine.